Industry Verticals »

All Categories

Insights »

About TMR »

Autoimmune Disease Therapeutics Market

Autoimmune Disease Therapeutics Market (By Drug Class: Biologics, Conventional Immunosuppressants, JAK Inhibitors, Corticosteroids, NSAIDs, Hormone & Replacement Therapies and Others; By Route of Administration: Oral, Subcutaneous (Injectable), Intravenous (Infusion), Topical and Others; By Disease Indication: Rheumatoid Arthritis, Psoriasis & Psoriatic Arthritis, Multiple Sclerosis, Crohn's Disease, Ulcerative Colitis, Systemic Lupus Erythematosus (SLE), Ankylosing Spondylitis & Axial Spondyloarthritis, Atopic Dermatitis, Autoimmune Thyroid Diseases, Type 1 Diabetes and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2026–2036

Autoimmune Disease Therapeutics Market Outlook 2036

The global autoimmune disease therapeutics market size was valued at USD 134.3 Billion in 2025 and is projected to reach USD 262.0 Billion by 2036, expanding at a CAGR of 6.3% from 2026 to 2036. The Market is driven by the rising prevalence and earlier diagnosis of conditions such as rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease, increasing the need for long-term disease management.

Market Size & Highlights

  • The Autoimmune Disease Therapeutics Market reached USD 134.3 Billion in 2025.
  • The market is expected to climb to USD 262.0 Billion by 2036.
  • The Autoimmune Disease Therapeutics industry is anticipated to expand at a CAGR of 6.3% from 2026 to 2036.
  • The major players in the market include AbbVie Inc., Johnson & Johnson, Sanofi, F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc. etc.
  • North America dominated the market in 2025, holding the largest revenue share of 39.6%
  • Rheumatoid Arthritis accounted for the largest market share of 29.6% in 2025

Autoimmune Disease Therapeutics Market By Revenue

Analysts’ Viewpoint

The global market for Autoimmune Disease Treatment is expected to grow steadily due to the high prevalence of autoimmune diseases as well as improved diagnosis, increased accessibility of treatment options, and the need for managing chronic conditions. Leading conditions, including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriatic arthritis, and systemic lupus erythematosus significantly drive demand for treatment.

The latest market analyses also reveal the growing influence of biologics, monoclonal antibodies, JAK inhibitors, and precision medicine on market growth. The trend here is changing from traditional broad immune suppression towards therapies that target the disease and modify it in the best way possible; therefore, drug manufacturers are becoming increasingly involved in improving the effectiveness, safety, and long-lasting results of treatment. Both biologics and targeted DMARDs are becoming widely used now, while biosimilars are contributing to increasing access to existing treatments and creating tougher competition in terms of pricing. Increased expenditure on the health care system, higher availability of reimbursements, earlier diagnosis of diseases, and new approvals by regulatory authorities facilitate the use of treatments.

Innovative drugs that modulate the immune system, such as the ones targeting B-cell activity, are creating new options in hard-to-treat autoimmune disorders. This situation is combined with significant efforts from pharma companies to secure new medicines, like partnerships and in-licensing of the novel immunotherapy products. As a result, it is expected that the increase in the number of patients diagnosed with the diseases, innovations in therapy, and patient requirements will contribute to the growth of this market in the investigated time period.

Market Introduction

Autoimmune disease therapeutics refer to medicines and treatment approaches used to manage autoimmune disorders in which the immune system mistakenly attacks the body's healthy cells, tissues, or organs. These therapies aim to suppress, regulate, or selectively modify abnormal immune responses, reduce inflammation, control disease progression, prevent organ damage, and improve patients' quality of life.

Attribute Detail
Market Drivers
  • Rising prevalence of autoimmune diseases
  • Growing adoption of biologics and targeted therapies

Rising Prevalence of Autoimmune Diseases Expected to Drive growth in the Autoimmune Disease Therapeutics Market

The rising incidence of Autoimmune Diseases is creating a need for medicines such as immunosuppressants, biologics, monoclonal antibodies, JAK inhibitors, and other kinds of treatment modalities. With the help of advanced diagnostics and greater education of medical professionals, patients are being diagnosed at an earlier stage which allows them to undergo treatment for various autoimmune diseases. Some of the latest studies show that there has been an increase in the incidence/prevalence of diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, the number of new cases being reported is expected to rise in the foreseeable future. Since autoimmune diseases are chronic in nature, there will be a constant demand in the pharmaceutical market for treating these diseases.

A rising incidence of autoimmune diseases is giving rise to an increasing need for the use of biologic agents, specifically medications classified as immunosuppressive drugs and monoclonal antibodies. The availability of advanced diagnostic methods and increased awareness of healthcare professionals in diagnosing autoimmune diseases support earlier diagnosis and the enable more patients to initiate treatment.

As autoimmune diseases are generally chronic and require prolonged management, the expanding treated population is expected to generate recurring pharmaceutical demand. The fact that autoimmune diseases are chronic and require long-term care means that a growing population of patients will create constant demand for medications. Thus, it is anticipated that all of these factors will drive growth in the market.

Growing adoption of biologics and targeted therapies Is Anticipated to Boost Expansion of the Autoimmune Disease Therapeutics Market

The increasing integration of biologics and targeted therapies is expected to support the growth of the Autoimmune Disease Therapeutics market. Traditional immunosuppressive therapies deliver generalized immunosuppression whereas biologics and targeted therapies act on specific immunological pathways and mechanisms which contribute to the progression of the autoimmune disease. This targeted mechanism can improve treatment effectiveness and clinical outcomes for patients that are inadequately managed with traditional therapies. For example, rheumatoid arthritis guidelines suggest the use of biologic DMARDs and targeted synthetic DMARDs with the use of traditional therapy. The increase in the availability of TNF inhibitors, IL inhibitors, B-cell targeting therapies, JAK inhibitors, and a variety of other monoclonal antibodies will help broaden the range of therapeutic options across rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, and lupus.

The emergence of biosimilars will also improve access and will boost competition thus contributing to the reduce treatment costs. Pharmaceutical companies continue to invest in advanced immune-modulation technologies and targeted therapeutic approaches. That is, recent industrial collaboration in terms of B-cell depletion reveals a growing interest in a highly selective methodology of treatment for autoimmune disorders. Therefore, continuing clinical applications, increased scope, improved efficiency, as well as new developments concerning targeted immune therapies mean that the Autoimmune Disease Therapeutics Market is expected to expand.

Attribute Detail
Market Opportunity
  • Emergence of cell-based therapies: CAR-T and other immune-cell therapies

Emergence of Cell-Based Therapies Expected to Create Opportunities for the Autoimmune Disease Therapeutics Market

The introduction of cell therapies, especially CAR-T therapy, is creating significant market opportunities for the Autoimmune Disease Therapeutics Market by providing a potential disease-modifying treatment option for patients with severe or treatment-resistant autoimmune disorders. Unlike standard treatment options, which usually require constant therapy to keep the immune system under control, CAR-T treatment selectively targets pathogenic immune cells and restores the improperly functioning immune response. Initial studies of CD19-targeted CAR-T therapies have shown remarkable results even in hard-to-treat diseases including systemic lupus erythematosus (SLE), systemic sclerosis, and inflammatory myopathies. The opportunity is especially pronounced in B-cell-mediated autoimmune diseases, knowing that the removal of abnormal B-cells might lead to decreased levels of antibodies and interrupted activity pathways in the immune system. New treatments are also being developed targeting plasma cells, dual-targeting CAR therapies, immune tolerance and using the so-called off-the-shelf cell therapies designed to improve accessibility.

Rheumatoid Arthritis Driving Autoimmune Disease Therapeutics Market Growth

Autoimmune Disease Therapeutics Market By Type

The rheumatoid arthritis segment dominated the global autoimmune disease therapeutics market in 2025, accounting for approximately 29.6% of total market, supported by its substantial patient population, chronic nature, and requirement for continuous pharmacological management. The disease creates significant long-term demand for therapeutics as patients often require sustained treatment to control inflammation, slow disease progression, and prevent irreversible joint damage.

The RA's leading position is supported by that there are many available conventional DMARDs, biologic DMARDs, monoclonal antibodies, and JAK inhibitors. These medications ensure long-term disease control of RA and continued treatment requirements. Biological medications are particularly significant in RA therapy, since these advanced drugs are usually used to treat those patients who have an inadequate response to conventional therapies. The RA treatment landscape also benefits from its established treatment protocols, advancements in diagnostics, growing awareness of the disease and increasing availability of specialists.

The emergence of targeted drugs has increased treatment options and provided physicians with the choice of therapies based on the severity of the disease, the patient’s response to treatment, and treatment history. Biosimilars have also increased access to existing biologic treatments and heightened competition in the market. Rheumatoid arthritis is one of the leading revenue-generating indications within the autoimmune therapeutics market. RA's treatment for a chronic disease, steady therapeutic field, biologic application, and development of the field overall signify its importance in the overall Autoimmune Disease Therapeutics Market.

Regional Outlook of Autoimmune Disease Therapeutics Market

Autoimmune Disease Therapeutics Market By Region

Attribute Detail
Leading Region
  • North America

North America dominated the global autoimmune disease therapeutics market in 2025, accounting for approximately [confirmed share 39.6% of total market revenue. High incidence and diagnosis of autoimmune disorders, advanced healthcare systems, and high adoption of advanced therapies are some of the major factors supporting North America's leading position in the Global Market. The U.S. contributes significantly to the demand for rheumatoid arthritis treatments, multiple sclerosis, lupus, psoriasis, and inflammatory bowel disease treatment.

High healthcare spending, efficient diagnostic technologies, a strong network of specialists, and the presence of biologics and target therapies provide North America with various advantages. Strong use of monoclonal antibodies, biologic DMARDs, JAK inhibitors, and other precision therapies supports revenues of the market in this region. The presence of major pharmaceutical and biotech companies in North America supports investment significantly in clinical research, drug development, and commercialization of novel therapies. access to specialized therapies, established reimbursement frameworks and the awareness brought by the rise in autoimmune disorders will contribute to treatment penetration. Another advantage is the availability of biosimilars which will also help improve access to biologic treatments.

Overall, the ability of pharmaceutical companies to engage in research and development, the acceptance of treatments, established healthcare infrastructure, and the increase in awareness of diseases are expected to support North America's leading position in the Autoimmune Disease Therapeutics Market.

Analysis of Key Players in Autoimmune Disease Therapeutics Market

AbbVie Inc., Johnson & Johnson, Novartis AG, Amgen Inc., Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Sanofi, UCB S.A., Takeda Pharmaceutical Company Limited, Biogen, Merck & Co., Inc., GSK plc, Boehringer Ingelheim, and Regeneron Pharmaceuticals, Inc. are among the prominent players operating in the global autoimmune disease therapeutics market.

Each of these players has been profiled in the Autoimmune Disease Therapeutics Market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments

  • In March 2026, Quantum BioPharma Ltd. announced that it has entered into a binding Letter of Intent (LOI) with Allucent to support the planned Phase 2 clinical trial of Lucid-MS for the treatment of multiple sclerosis (MS). The planned Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with MS.
  • In May 2026, Accord BioPharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved IMMGOLIS (golimumab-sldi), a biosimilar to Simponi (golimumab), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate, and adult patients with moderately to severely active ulcerative colitis (UC).
  • In July 2025, SetPoint Medical, announced that the U.S. Food and Drug Administration (FDA) approved the company’s SetPoint System, a breakthrough innovation for people with rheumatoid arthritis (RA). The SetPoint System is a first-of-its-kind neuroimmune modulation device for the treatment of adults living with moderate-to-severe RA who are not adequately managed by—or cannot tolerate—existing advanced RA therapies, such as biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs).

Autoimmune Disease Therapeutics Market Snapshot

Attribute Detail
Size in 2025 USD 134.3 Billion
Forecast Value in 2036 USD 262.0 Billion
CAGR 6.3%
Forecast Period 2026-2036
Historical Data Available for 2021-2025
Quantitative Units USD Billion for Value
Autoimmune Disease Therapeutics Market Analysis It includes segment analysis as well as regional level analysis. Qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape
  • Competition Matrix
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Segmentation By Drug Class
  • Biologics
    • TNF Inhibitors
    • IL Inhibitors
    • Interferons
    • B-cell Inhibitors
    • Other Biologics
  • Conventional Immunosuppressants
  • JAK Inhibitors
  • Corticosteroids
  • NSAIDs
  • Hormone & Replacement Therapies
  • Others
By Route of Administration
  • Oral
  • Subcutaneous (Injectable)
  • Intravenous (Infusion)
  • Topical
  • Others
By Disease Indication
  • Rheumatoid Arthritis
  • Psoriasis & Psoriatic Arthritis
  • Multiple Sclerosis
  • Crohn's Disease
  • Ulcerative Colitis
  • Systemic Lupus Erythematosus (SLE)
  • Ankylosing Spondylitis & Axial Spondyloarthritis
  • Atopic Dermatitis
  • Autoimmune Thyroid Diseases
  • Type 1 Diabetes
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • The Netherlands
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • ASEAN
  • Brazil
  • Mexico
  • Argentina
  • GCC Countries
  • South Africa
Companies Profiled
  • AbbVie Inc.
  • Johnson & Johnson and its affiliates
  • Sanofi
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Amgen Inc.
  • Pfizer Inc.
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • Biogen
  • UCB S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca
  • Others
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global autoimmune disease therapeutics market in 2025?

The market was valued at USD 134.3 Billion in 2025

What is the projected size of the autoimmune disease therapeutics industry by 2036?

The industry is projected reach USD 262.0 Billion by 2036

What are the factors driving the autoimmune disease therapeutics market?

Rising prevalence of autoimmune diseases and growing adoption of biologics and targeted therapies.

What is the expected CAGR of the global autoimmune disease therapeutics market during the forecast period?

The global market is anticipated to grow at a CAGR of 6.3% from 2026 to 2036

Which region is expected to dominate the autoimmune disease therapeutics market during the forecast period?

North America is expected to hold the largest market share during the forecast period

Who are the prominent autoimmune disease therapeutics market providers?

AbbVie Inc., Johnson & Johnson, Novartis AG, Amgen Inc., Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Sanofi, UCB S.A., Takeda Pharmaceutical Company Limited, Biogen, Merck & Co., Inc., GSK plc, Boehringer Ingelheim, and Regeneron Pharmaceuticals, Inc. among others.

  1. Preface
    • Market Definition and Scope
    • Market Segmentation
    • Key Research Objectives
    • Research Highlights
  2. Assumptions and Research Methodology
  3. Executive Summary: Global Autoimmune Disease Therapeutics Market
  4. Market Overview
    • Introduction
      • Segment Definition
      • Industry Evolution / Developments
    • Overview
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunities
    • Global Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021–2036
      • Market Revenue Projections (USD Bn)
  5. Key Insights
    • JAK Inhibitor Adoption Trends
    • Biosimilar Penetration Assessment
    • Precision Medicine Landscape Analysis
    • Disease Indication Opportunity Analysis
    • Targeted Immunotherapy Adoption Trends
    • Self-Administration Treatment Trends
    • Pipeline Drug Assessment
    • Reimbursement and Market Access Analysis
    • Product Benchmarking
    • Regulatory and Approval Landscape
    • Mergers, Acquisitions, and Partnerships Analysis
  6. Global Autoimmune Disease Therapeutics Market Analysis and Forecast, by Drug Class
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Attractiveness Analysis, by Drug Class
  7. Global Autoimmune Disease Therapeutics Market Analysis and Forecast, by Route of Administration
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Attractiveness Analysis, by Route of Administration
  8. Global Autoimmune Disease Therapeutics Market Analysis and Forecast, by Indication
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Attractiveness Analysis, by Indication
  9. Global Autoimmune Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis, by Distribution Channel
  10. Global Autoimmune Disease Therapeutics Market Analysis and Forecast, by Region
    • Key Findings
    • Market Value Forecast, by Region, 2021–2036
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa
    • Market Attractiveness Analysis, by Region
  11. North America Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Value Forecast, by Country/Sub-region, 2021–2036
      • U.S.
      • Canada
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
      • By Country/Sub-region
  12. U.S. Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  13. Canada Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  14. Europe Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Value Forecast, by Country/Sub-region, 2021–2036
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • The Netherlands
      • Switzerland
      • Rest of Europe
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
      • By Country/Sub-region
  15. Germany Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  16. U.K. Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  17. France Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  18. Italy Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  19. Spain Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  20. The Netherlands Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  21. Switzerland Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  22. Rest of Europe Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  23. Asia Pacific Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Value Forecast, by Country/Sub-region, 2021–2036
      • China
      • India
      • Japan
      • South Korea
      • Australia and New Zealand
      • Rest of Asia Pacific
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
      • By Country/Sub-region
  24. China Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  25. India Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  26. Japan Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  27. South Korea Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  28. Australia and New Zealand Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  29. Rest of Asia Pacific Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  30. Latin America Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Value Forecast, by Country/Sub-region, 2021–2036
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
      • By Country/Sub-region
  31. Brazil Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  32. Mexico Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  33. Argentina Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  34. Rest of Latin America Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  35. Middle East & Africa Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Value Forecast, by Country/Sub-region, 2021–2036
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
      • By Country/Sub-region
  36. GCC Countries Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  37. South Africa Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  38. Rest of Middle East & Africa Autoimmune Disease Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021–2036
      • Biologics
        • Monoclonal Antibodies
        • Fusion Proteins
        • Cytokine/Interleukin Inhibitors
        • Others
      • Immunosuppressants
        • Methotrexate
        • Cyclosporine
        • Azathioprine
        • Others
      • Anti-inflammatory Drugs
        • NSAIDs
        • Other Anti-inflammatory Drugs
      • Corticosteroids
      • Disease-Modifying Antirheumatic Drugs (DMARDs)
        • Conventional Synthetic DMARDs
        • Targeted Synthetic DMARDs
      • Interferons
      • Hormone/Replacement Therapies
      • Others
    • Market Value Forecast, by Route of Administration, 2021–2036
      • Oral
      • Injectable
      • Intravenous
      • Topical
      • Other Routes
    • Market Value Forecast, by Indication, 2021–2036
      • Rheumatoid Arthritis
      • Psoriasis & Psoriatic Arthritis
      • Inflammatory Bowel Disease
      • Multiple Sclerosis
      • Systemic Lupus Erythematosus (SLE)
      • Ankylosing Spondylitis & Axial Spondyloarthritis
      • Atopic Dermatitis
      • Autoimmune Thyroid Diseases
      • Type 1 Diabetes
      • Others
    • Market Value Forecast, by Distribution Channel, 2021–2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Specialty Pharmacies
      • Online Pharmacies
      • Sports Medicine Centers
      • Home Care Settings
    • Market Attractiveness Analysis
      • By Drug Class
      • By Route of Administration
      • By Indication
      • By Distribution Channel
  39. Competition Landscape
    • Market Player – Competition Matrix (By Tier and Size of Companies)
    • Market Share Analysis, by Company (2025)
    • Company Profiles
      • AbbVie Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Johnson & Johnson
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Novartis AG
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Amgen Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Pfizer Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Bristol Myers Squibb
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Eli Lilly and Company
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • F. Hoffmann-La Roche Ltd.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Sanofi
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • UCB S.A.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Biogen
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Merck & Co., Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • GSK plc
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Boehringer Ingelheim
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Regeneron Pharmaceuticals, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments

List of Tables

Table 01: Global Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 02: Global Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 03: Global Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 04: Global Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 05: Global Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 06: Global Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Country/Sub-region, 2021 to 2036
Table 07: North America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 08: North America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 09: North America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 10: North America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 11: North America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 12: North America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Country/Sub-region, 2021 to 2036
Table 13: U.S. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 14: U.S. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 15: U.S. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 16: U.S. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 17: U.S. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 18: Canada Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 19: Canada Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 20: Canada Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 21: Canada Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 22: Canada Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 23: Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 24: Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 25: Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 26: Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 27: Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 28: Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Country/Sub-region, 2021 to 2036
Table 29: Germany Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 30: Germany Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 31: Germany Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 32: Germany Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 33: Germany Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 34: U.K. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 35: U.K. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 36: U.K. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 37: U.K. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 38: U.K. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 39: France Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 40: France Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 41: France Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 42: France Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 43: France Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 44: Italy Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 45: Italy Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 46: Italy Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 47: Italy Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 48: Italy Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 49: Spain Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 50: Spain Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 51: Spain Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 52: Spain Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 53: Spain Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 54: Switzerland Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 55: Switzerland Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 56: Switzerland Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 57: Switzerland Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 58: Switzerland Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 59: The Netherlands Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 60: The Netherlands Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 61: The Netherlands Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 62: The Netherlands Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 63: The Netherlands Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 64: Rest of Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 65: Rest of Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 66: Rest of Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 67: Rest of Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 68: Rest of Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 69: Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 70: Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 71: Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 72: Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 73: Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 74: Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Country/Sub-region, 2021 to 2036
Table 75: China Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 76: China Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 77: China Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 78: China Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 79: China Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 80: Japan Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 81: Japan Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 82: Japan Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 83: Japan Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 84: Japan Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 85: India Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 86: India Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 87: India Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 88: India Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 89: India Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 90: South Korea Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 91: South Korea Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 92: South Korea Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 93: South Korea Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 94: South Korea Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 95: Australia and New Zealand Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 96: Australia and New Zealand Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 97: Australia and New Zealand Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 98: Australia and New Zealand Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 99: Australia and New Zealand Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 100: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 101: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 102: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 103: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 104: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 105: Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 106: Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 107: Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 108: Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 109: Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 110: Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Country/Sub-region, 2021 to 2036
Table 111: Brazil Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 112: Brazil Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 113: Brazil Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 114: Brazil Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 115: Brazil Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 116: Mexico Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 117: Mexico Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 118: Mexico Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 119: Mexico Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 120: Mexico Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 121: Argentina Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 122: Argentina Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 123: Argentina Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 124: Argentina Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 125: Argentina Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 126: Rest of Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 127: Rest of Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 128: Rest of Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 129: Rest of Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 130: Rest of Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 131: Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 132: Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 133: Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 134: Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 135: Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 136: Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Country/Sub-region, 2021 to 2036
Table 137: GCC Countries Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 138: GCC Countries Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 139: GCC Countries Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 140: GCC Countries Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 141: GCC Countries Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 142: South Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 143: South Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 144: South Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 145: South Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 146: South Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036
Table 147: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Drug Class, 2021 to 2036
Table 148: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Biologics, 2021 to 2036
Table 149: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Route of Administration, 2021 to 2036
Table 150: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Disease Indication, 2021 to 2036
Table 151: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, by Distribution Channel, 2021 to 2036

List of Figures

Figure 01: Global Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 02: Global Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 03: Global Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 04: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Biologics, 2021 to 2036
Figure 05: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Conventional Immunosuppressants, 2021 to 2036
Figure 06: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by JAK Inhibitors, 2021 to 2036
Figure 07: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Corticosteroids, 2021 to 2036
Figure 08: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by NSAIDs, 2021 to 2036
Figure 09: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Hormone & Replacement Therapies, 2021 to 2036
Figure 10: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Others, 2021 to 2036
Figure 11: Global Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 12: Global Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 13: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Oral, 2021 to 2036
Figure 14: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Subcutaneous (Injectable), 2021 to 2036
Figure 15: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Intravenous (Infusion), 2021 to 2036
Figure 16: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Topical, 2021 to 2036
Figure 17: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Others, 2021 to 2036
Figure 18: Global Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 19: Global Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 20: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Rheumatoid Arthritis, 2021 to 2036
Figure 21: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Psoriasis & Psoriatic Arthritis, 2021 to 2036
Figure 22: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Multiple Sclerosis, 2021 to 2036
Figure 23: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Crohn's Disease, 2021 to 2036
Figure 24: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Ulcerative Colitis, 2021 to 2036
Figure 25: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Systemic Lupus Erythematosus (SLE), 2021 to 2036
Figure 26: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Ankylosing Spondylitis & Axial Spondyloarthritis, 2021 to 2036
Figure 27: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Atopic Dermatitis, 2021 to 2036
Figure 28: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Autoimmune Thyroid Diseases, 2021 to 2036
Figure 29: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Type 1 Diabetes, 2021 to 2036
Figure 30: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Others, 2021 to 2036
Figure 31: Global Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 32: Global Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 33: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Hospital Pharmacies, 2021 to 2036
Figure 34: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Retail Pharmacies, 2021 to 2036
Figure 35: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Specialty Pharmacies, 2021 to 2036
Figure 36: Global Autoimmune Disease Therapeutics Market Revenue (USD Bn), by Online Pharmacies, 2021 to 2036
Figure 37: Global Autoimmune Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 38: Global Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 39: North America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 40: North America Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 41: North America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 42: North America Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 43: North America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 44: North America Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 45: North America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 46: North America Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 47: North America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 48: North America Autoimmune Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 49: North America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 50: U.S. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 51: U.S. Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 52: U.S. Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 53: U.S. Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 54: U.S. Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 55: U.S. Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 56: U.S. Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 57: U.S. Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 58: U.S. Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 59: Canada Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 60: Canada Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 61: Canada Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 62: Canada Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 63: Canada Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 64: Canada Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 65: Canada Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 66: Canada Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 67: Canada Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 68: Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 69: Europe Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 70: Europe Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 71: Europe Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 72: Europe Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 73: Europe Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 74: Europe Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 75: Europe Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 76: Europe Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 77: Europe Autoimmune Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 78: Europe Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 79: Germany Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 80: Germany Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 81: Germany Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 82: Germany Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 83: Germany Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 84: Germany Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 85: Germany Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 86: Germany Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 87: Germany Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 88: U.K. Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 89: U.K. Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 90: U.K. Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 91: U.K. Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 92: U.K. Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 93: U.K. Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 94: U.K. Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 95: U.K. Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 96: U.K. Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 97: France Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 98: France Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 99: France Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 100: France Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 101: France Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 102: France Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 103: France Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 104: France Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 105: France Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 106: Italy Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 107: Italy Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 108: Italy Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 109: Italy Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 110: Italy Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 111: Italy Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 112: Italy Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 113: Italy Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 114: Italy Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 115: Spain Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 116: Spain Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 117: Spain Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 118: Spain Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 119: Spain Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 120: Spain Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 121: Spain Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 122: Spain Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 123: Spain Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 124: Switzerland Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 125: Switzerland Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 126: Switzerland Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 127: Switzerland Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 128: Switzerland Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 129: Switzerland Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 130: Switzerland Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 131: Switzerland Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 132: Switzerland Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 133: The Netherlands Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 134: The Netherlands Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 135: The Netherlands Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 136: The Netherlands Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 137: The Netherlands Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 138: The Netherlands Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 139: The Netherlands Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 140: The Netherlands Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 141: The Netherlands Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 142: Rest of Europe Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 143: Rest of Europe Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 144: Rest of Europe Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 145: Rest of Europe Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 146: Rest of Europe Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 147: Rest of Europe Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 148: Rest of Europe Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 149: Rest of Europe Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 150: Rest of Europe Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 151: Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 152: Asia Pacific Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 153: Asia Pacific Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 154: Asia Pacific Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 155: Asia Pacific Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 156: Asia Pacific Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 157: Asia Pacific Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 158: Asia Pacific Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 159: Asia Pacific Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 160: Asia Pacific Autoimmune Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 161: Asia Pacific Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 162: China Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 163: China Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 164: China Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 165: China Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 166: China Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 167: China Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 168: China Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 169: China Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 170: China Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 171: Japan Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 172: Japan Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 173: Japan Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 174: Japan Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 175: Japan Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 176: Japan Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 177: Japan Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 178: Japan Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 179: Japan Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 180: India Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 181: India Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 182: India Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 183: India Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 184: India Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 185: India Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 186: India Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 187: India Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 188: India Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 189: South Korea Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 190: South Korea Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 191: South Korea Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 192: South Korea Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 193: South Korea Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 194: South Korea Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 195: South Korea Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 196: South Korea Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 197: South Korea Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 198: Australia and New Zealand Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 199: Australia and New Zealand Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 200: Australia and New Zealand Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 201: Australia and New Zealand Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 202: Australia and New Zealand Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 203: Australia and New Zealand Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 204: Australia and New Zealand Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 205: Australia and New Zealand Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 206: Australia and New Zealand Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 207: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 208: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 209: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 210: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 211: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 212: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 213: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 214: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 215: Rest of Asia Pacific Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 216: Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 217: Latin America Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 218: Latin America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 219: Latin America Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 220: Latin America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 221: Latin America Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 222: Latin America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 223: Latin America Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 224: Latin America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 225: Latin America Autoimmune Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 226: Latin America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 227: Brazil Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 228: Brazil Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 229: Brazil Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 230: Brazil Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 231: Brazil Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 232: Brazil Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 233: Brazil Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 234: Brazil Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 235: Brazil Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 236: Mexico Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 237: Mexico Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 238: Mexico Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 239: Mexico Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 240: Mexico Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 241: Mexico Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 242: Mexico Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 243: Mexico Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 244: Mexico Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 245: Argentina Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 246: Argentina Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 247: Argentina Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 248: Argentina Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 249: Argentina Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 250: Argentina Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 251: Argentina Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 252: Argentina Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 253: Argentina Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 254: Rest of Latin America Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 255: Rest of Latin America Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 256: Rest of Latin America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 257: Rest of Latin America Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 258: Rest of Latin America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 259: Rest of Latin America Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 260: Rest of Latin America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 261: Rest of Latin America Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 262: Rest of Latin America Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 263: Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 264: Middle East and Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 265: Middle East and Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 266: Middle East and Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 267: Middle East and Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 268: Middle East and Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 269: Middle East and Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 270: Middle East and Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 271: Middle East and Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 272: Middle East and Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 273: Middle East and Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 274: GCC Countries Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 275: GCC Countries Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 276: GCC Countries Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 277: GCC Countries Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 278: GCC Countries Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 279: GCC Countries Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 280: GCC Countries Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 281: GCC Countries Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 282: GCC Countries Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 283: South Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 284: South Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 285: South Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 286: South Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 287: South Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 288: South Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 289: South Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 290: South Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 291: South Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 292: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Value (USD Bn) Forecast, 2021 to 2036
Figure 293: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 294: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 295: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 296: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 297: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Disease Indication, 2025 and 2036
Figure 298: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Disease Indication, 2026 to 2036
Figure 299: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 300: Rest of Middle East and Africa Autoimmune Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036

Copyright © Transparency Market Research, Inc. All Rights reserved

Autoimmune Disease Therapeutics Market

Buy This ReportBuy Now